PIRS

In this article we take a look at the 25 best U.S. cities to live with asthma. Click to skip ahead and jump to the 10 best U.S. cities to live with asthma. Navigating through life with asthma can be a life-long challenge in itself. Sometimes it becomes very important to constantly monitor your surroundings […]

/ , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q3 results.Quarterly Results Earnings per share were down 420.00% over the past year to ($0.26), which missed the estimate of ($0.13).Revenue of $2,939,000 declined by 80.58% year over year, which missed the estimate of $9,790,000.Guidance Pieris Pharmaceuticals hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Nov 04, 2020View more earnings on PIRSTime: 08:00 AMET Webcast URL: https://www.pieris.com/news-and-events/upcoming-eventsPrice Action Company's 52-week high was at $4.3052-week low: $1.60Price action over last quarter: down 20.89%Company Overview Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 4, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Pieris Pharmaceuticals (PIRS): Q3 GAAP EPS of -$0.26 misses by $0.13.Revenue of $2.94M (-80.6% Y/Y) misses by $8.78M.Press Release

NEW YORK, NY / ACCESSWIRE / November 4, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 4, 2020 at 8:00 AM Eastern Time.

BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, 2020 at 8:00 AM EST to discuss financial results and provide a corporate update.

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress